Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:18:05.889Z.
Calculation as of: 2026-10-06T20:18:05.889Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80dc1f4e8b31b1f0ec5b4a1e5c631a71efe14c3ee5142d993ef0c896d26e8132
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$127.29M
EBITDA Yield
N/A
TTM Avg
0.18%
3Y Avg
0.16%
5Y Avg
0.16%
Market Cap
$130.79M
EBITDA Yield
1.34%
TTM Avg
1.37%
3Y Avg
1.37%
5Y Avg
1.37%
Market Cap
$131.21M
EBITDA Yield
0.23%
TTM Avg
0.33%
3Y Avg
3.24%
5Y Avg
2.95%
Market Cap
$122.66M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | $127.98M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A | 0.18% | 0.16% | 0.16% |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | 1.34% | 1.37% | 1.37% | 1.37% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | 0.23% | 0.33% | 3.24% | 2.95% |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | N/A | 27.23% | 27.23% | 27.23% |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $132.03M | N/A | 4.68% | 4.68% | 4.68% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
